Role of TGF-β1 and MAP kinases in the antiproliferative effect of aspirin in human vascular smooth muscle cells

PLoS ONE

Volumn 5, Issue 3, 2010, Pages

  Redondo, Santiago ^a   Ruiz, Emilio ^a   Gordillo Moscoso, Antonio ^a   Navarro Dorado, Jorge ^a   Ramajo, Marta ^a   Carnero, Manuel ^b   Reguillo, Fernando ^b   Rodriguez, Enrique ^b   Tejerina, Teresa ^a  

^a SCHOOL OF MEDICINE   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; ANTITHROMBOCYTIC AGENT; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; LACTATE DEHYDROGENASE; LEUKOCYTE ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE P38; TRANSFORMING GROWTH FACTOR BETA1;

AGED; ARTICLE; BIOSYNTHESIS; CELL PROLIFERATION; CORONARY ARTERY BYPASS GRAFT; CULTURE MEDIUM; CYTOLOGY; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE;

AGED; ANTI-INFLAMMATORY AGENTS; ANTIGENS, CD; ASPIRIN; CELL PROLIFERATION; CORONARY ARTERY BYPASS; CULTURE MEDIA, CONDITIONED; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PLATELET AGGREGATION INHIBITORS; RECEPTORS, CELL SURFACE; TRANSFORMING GROWTH FACTOR BETA1;

EID: 77956410875     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009800     Document Type: Article

References (31)

1. Antiplatelet Trialists' Collaboration (1994) Collaborative overview of randomized trials of antiplatelet therapy I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308: 81-106.
2. Antiplatelet Trialists' Collaboration (2002) Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324: 71-86.
3. Marra DE, Simoncini T, Liao JK (2000) Inhibition of vascular smooth muscle cell proliferation by sodium salicylate mediated by upregulation of p21(Waf1) and p27(Kip1). Circulation 102: 2124-2130.
4. Redondo S, Santos-Gallego CG, Ganado P, Garcia M, Rico L, et al. (2003) Acetylsalicylic acid inhibits cell proliferation by involving transforming growth factor beta. Circulation 107: 626-629.
5. Ranke C, Hecker H, Creutzig A, Alexander K (1993) Dose-dependent effect of ASA on carotid atherosclerosis. Circulation 87: 1873-1879.
6. Grainger DJ, Kemp PR, Metcalfe JC, Liu AC, Lawn RM, et al. (1995) Concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis. Nat Med 1: 74-79.
7. Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, et al. (1999) Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 100: 793-798.
8. Redondo S, Santos-Gallego CG, Tejerina T (2007) TGF-beta1: a novel target for cardiovascular pharmacology. Cytokine Growth Factor Rev 8: 279-286.
9. Ruiz E, Redondo E, Gordillo-Moscoso A, Tejerina T (2007) Pioglitazone induces apoptosis in human vascular smooth muscle cells from diabetic patients involving the transforming growth factor-beta/activin receptor-like kinase-4/5/ 7/Smad2 signaling pathway. J Pharmacol Exp Ther 321: 431-438.
10. Seay U, Sedding D, Krick S, Hecker M, Seeger W, et al. (2005) Transforming growth factor-beta-dependent growth inhibition in primary vascular smooth muscle cells is p38-dependent. J Pharmacol Exp Ther 315: 1005-1012.
11. Amann R, Peskar BA (2002) Anti-inflammatory effects of aspirin and sodium salicylate. Eur J Pharmacol 447: 1-9.
12. Redondo S, Ruiz E, Santos-Gallego CG, Padilla E, Tejerina T (2005) Pioglitazone induces vascular smooth muscle cell apoptosis through a peroxisome proliferator-activated receptor-gamma, transforming growth factor-beta1, and a Smad2-dependent mechanism. Diabetes 54: 811-817.
13. Schwenger P, Alpert D, Skolnik EY, Vilcek J (1998) Activation of p38 mitogenactivated protein kinase by sodium salicylate leads to inhibition of tumor necrosis factor-induced IkappaB alpha phosphorylation and degradation. Mol Cell Biol 18: 78-84.
14. Awtry EH, Loscalzo J (2000) Aspirin. Circulation 101: 1206-1218.
15. Patrono C (2003) Aspirin resistance: definition, mechanisms and clinical readouts. J Thromb Haemost 1: 1710-1713.
16. Okrainec K, Platt R, Pilote L, Eisenberg MJ (2005) Cardiac medical therapy in patients after undergoing coronary artery bypass graft surgery: a review of randomized controlled trials. J Am Coll Cardiol 45: 177-184.
17. Refson JS, Schachter M, Patel MK, Hughes AD, Munro E, et al. (1998) Vein graft stenosis and the heparin responsiveness of human vascular smooth muscle cells. Circulation 97: 2506-2510.
18. Ranke C, Creutzig A, Luska G, Wagner HH, Galanski M, et al. (1994) Controlled trial of high-versus low-dose aspirin treatment after percutaneous transluminal angioplasty in patients with peripheral vascular disease. J Clin Invest 2: 673-680.
19. Weber C (2005) Platelets and chemokines in atherosclerosis: partners in crime. Circ Res 96: 612-616.
20. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, et al. (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354: 1706-1717.
21. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, et al. (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352: 1179-1189.
22. Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, et al. (2004) Clopidogrel in Unstable angina to prevent Recurrent ischemic Events Trial, Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 110: 1202-1208.
23. Koh JY, Choi DW (1987) Quantitative determination of glutamate mediated cortical neuronal injury in cell culture by lactate dehydrogenase efflux assay. J Neurosci Methods 20: 83-90.
24. Schmidt-Weber CB, Letarte M, Kunzmann S, Ruckert B, Bernabeu C, et al. (2005) TGF-B signalling in human T cells is modulated by the ancillary TGF-B receptor endoglin. Int Immunol 17: 921-930.
25. Grainger DJ (2004) Transforming growth beta and atherosclerosis: so far so good for the protective cytokine hypothesis. Arterioscl Thromb Vasc Biol 24: 399-404.
26. Siegert A, Ritz E, Orth E, Wagner J (1999) Differential regulation of transforming growth factor receptors by angiotensin II and transforming growth factor-beta1 in vascular smooth muscle. J Mol Med 77: 437-445.
27. Kropf J, Schurek JO, Wollner A, Gressner AM (1997) Immunological measurement of transforming growth factor-beta 1 (TGF-beta1) in blood; assay development and comparison. Clin Chem 43: 1965-1974.
28. Redondo S, Ruiz E, Padilla E, Gordillo-Moscoso A, Tejerina T (2007) Role of TGF beta in vascular smooth muscle cell apoptosis induced by angiotensin II. Eur J Pharmacol 556: 36-44.
29. Ansari HR, Teng B, Nadeem A, Roush KP, Martin KH, et al. (2009) A(1) adenosine receptor-mediated PKC and p42/p44 MAPK signaling in mouse coronary artery smooth muscle cells. Am J Physiol Heart Circ Physiol 297: H1032-H1039.
30. DaCosta Byfield S, Major C, Laping NJ, Roberts AB (2004) SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7. Mol Pharmacol 65: 744-752.
31. Ivanov VO, Rabovsky AB, Ivanova SV, Niedzwiecki A (1998) Transforming growth factor-beta 1 and ascorbate regulate proliferation of cultured smooth muscle cells by independent mechanisms. Atherosclerosis 140: 25-34.